We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

By LabMedica International staff writers
Posted on 25 Jun 2024
Print article
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) now deliver combined results for complete blood count (CBC)/differential (DIFF) and ESR from whole blood in just 60 seconds. This integration provides a more comprehensive assessment of inflammatory diseases, adding significant value to the instruments' existing extensive functionalities.

The integration of ESR into its three new analyzers has been made possible through HORIBA's innovative CoRA (Correlated Rouleaux Analysis) technology. By combining CBC and 5-population white blood cell DIFF with rapid ESR, calibrated to the Westergren reference method, these compact analyzers can reduce both costs per test and turnaround times, while also saving laboratory space. Additionally, both the Yumizen H550E and H500E models feature enhanced connectivity for data management through HORIBA’s Yumizen P8000 middleware and Yumicare, a remote technical support tool that ensures secure connections to the instruments for monitoring workload, reagent consumption, quality control, and instrument alarms.

The evolution of the Yumizen H550 range has also seen the inclusion of i-DoubleDiff technologies, which utilize artificial intelligence (AI) to provide score flags for infectious diseases such as malaria and dengue fever. This feature enhances the diagnostic speed and expands the utility of the analyzers in diverse medical environments, including both advanced and resource-limited settings. DoubleDiff technology further supports the addition of Normal leucocyte count (Lymphocyte, Monocyte, Neutrophil, Eosinophil, Basophil) + Abnormal leucocyte count (IMG, IMM, IML, LIC, ALY). With just two reagents, this technology has expanded the analytical capabilities of the analyzers from 27 to 37 parameters, offering deeper insights and more comprehensive results, especially in oncology. Thanks to its advanced technologies, affordability, reliability, and simplicity, the Yumizen H550 range is well-suited for a variety of clinical settings, including critical care, oncology, infectious disease management, blood banks, satellite laboratories, and health centers.

“Building on the global success of our previous Yumizen H550 range, we have designed the new analyzers to meet the increasing demand for affordable, robust, and highly capable hematology analyzers with connectivity that are suitable for any lab environment,” said Arnaud Pradel, President, HORIBA ABX SAS. “It is one instrument with endless possibilities, and the capabilities of our Yumizen H550 range continue to grow to meet even more clinical lab needs.”

Related Links:
HORIBA

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.